Clinic Network Expansion BrainsWay is expanding its Deep TMS footprint in North America through partnerships with leading mental health providers and clinics, including investments in provider servicing networks in Illinois, enabling broader access and scalable installations.

Robust Clinical Evidence FDA-cleared indications including anxious depression, obsessive compulsive disorder, and smoking cessation, backed by pivotal studies, plus ongoing trials across psychiatric, neurological, and addiction disorders, support market differentiation and partner adoption.

Financial Momentum The company shows revenue growth and fundraising signals that support expansion of device placements and the development of a recurring revenue base through service, maintenance, and training offerings for health systems and clinics.

Accelerated TMS Value New data on accelerated Deep TMS protocols demonstrate durability and meaningful remission outcomes, providing a compelling case for clinics seeking efficient, high-impact treatments and opportunities to upgrade existing installations.

Global Leadership With offices in the United States and Israel and a global leadership position in noninvasive neurostimulation, BrainsWay offers collaboration opportunities with hospitals, researchers, and payers to expand access and gather real-world evidence.